Assessment of Global Risk: A Foundation for a New, Better Definition of Hypertension
Version of Record online: 22 MAY 2007
The Journal of Clinical Hypertension
Volume 8, Issue Supplement s8, pages 5–14, August 2006
How to Cite
Giles, T. D. (2006), Assessment of Global Risk: A Foundation for a New, Better Definition of Hypertension. The Journal of Clinical Hypertension, 8: 5–14. doi: 10.1111/j.1524-6175.2006.05835.x
- Issue online: 22 MAY 2007
- Version of Record online: 22 MAY 2007
- 1and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347 – 1360., , , et al.,
- 2Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217 – 223., , , et al.
- 3Residual life-time risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003 – 1010., , , et al.
- 4on behalf of the Hypertension Writing Group. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich). 2005;7:505 – 512., , , et al.,
- 5Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(suppl 1):3S – 10S..
- 6Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003;16(11 pt 2):41S – 45S..
- 7Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486 – 2497.
- 8Profiling of the secreted proteins during 3T3-L1 adipocyte differentiation leads to the identification of novel adipokines. Cell Mol Life Sci. 2004;61:2405 – 2417., , , et al.
- 9The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560 – 2572.
- 10Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444 – 2449., , .
- 11The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care. 2005;28:882 – 887., , , et al.
- 12Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism. 1999;48:989 – 994., , , et al.
- 13Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91(suppl 1):30H – 37H., , .
- 14Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115 – 126.
- 15Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973 – 979., , , et al.
- 16Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933 – 937..
- 17on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937 – 952., , , et al.,
- 18Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004;44:859 – 865., , , et al.
- 19Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 – 1913.
- 20Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955 – 1964.
- 21Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701 – 709., , , et al.
- 22Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305 – 1315., , .
- 23Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245 – 1249., , , et al.
- 24Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199 – 206., .
- 25Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60 – 69., , , et al.
- 26Birth cohort evidence of population influences on blood pressure in the United States, 1887–1994. Ann Epidemiol. 2001;11:271 – 279., , , et al.
- 27for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646 – 661., , , et al.,
- 28for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393 – 404., , , et al.,
- 29for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755 – 1762., , , et al.,
- 30UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703 – 713.
- 31PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033 – 1041.
- 32for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217 – 2226., , , et al.,
- 33for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685 – 1697., , , et al.,
- 34and the TROPHY Study Investigators. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005;18:980 – 985., , , et al.,
- 35National Committee for Quality Assurance. The State of Health Care Quality: 2005. Available at: http://www.ncqa.org/Communications/News/SOHC_2005.htm. Accessed May 10, 2006.